The Biosecure Act, recently passed by the US House of Representatives, marks a significant escalation in efforts to decouple the American and Chinese biotech ecosystems. The bill, which passed with strong bipartisan support, would prohibit federal funding for US companies that do business with several named Chinese biotech firms, including industry giants Wuxi AppTec and BGI Genomics.This move reflects growing concerns in Washington about China’s ambitions in the life sciences and the…
Read More…
Opinion | Is biotech the next battleground in US-China decoupling?
